Mereo BioPharma is sponsoring a multi-centre international clinical trial to study the effects of anti-sclerostin therapy drug Setrusumab (previously called BPS804)on bone in OI. The study has now started recruiting patients in the UK, and at multiple sites across Europe, the United States, and Canada. Adults between 18 and 75 years old who have a diagnosis of OI Types I, III, or IV may be eligible for this 1-year clinical research study, which aims to enrol up to 140 patients.
Visit the Clinical Trials website or theAsteroid Study website to learn more, find your nearest study location, and register your interest in participation. If you have any additional questions, please email theAsteroid Study team. Their study contacts will be able to tell you more about the clinical research study, review eligibility criteria, and find a site near you.